Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Nurofen Tension Headache 342mg caplets
1001010ADBDAAAB
|
Nurofen Tension Headache | Ibuprofen lysine | Musculoskeletal and Joint Diseases | No data available |
|
Nycopren 250mg gastro-resistant tablets
1001010P0BGAAAH
|
Nycopren | Naproxen | Musculoskeletal and Joint Diseases | No data available |
|
Nycopren 500mg gastro-resistant tablets
1001010P0BGABAI
|
Nycopren | Naproxen | Musculoskeletal and Joint Diseases | No data available |
|
Odour Free Lloyds cream
1003020I0BDAAAA
|
Odour Free Lloyds | Diethylamine salicylate | Musculoskeletal and Joint Diseases | No data available |
|
Olumiant 2mg tablets
1001030ACBBABAB
|
Olumiant | Baricitinib | Musculoskeletal and Joint Diseases | No data available |
|
Onsenal 400mg capsules
1001010AHBCAAAD
|
Onsenal | Celecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Orbifen For Children 100mg/5ml oral suspension
1001010J0CRAABH
|
Orbifen | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Orbifen For Children 100mg/5ml oral suspension 5ml sachets
1001010J0CRABBM
|
Orbifen | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Orencia 125mg/1ml solution for injection pre-filled syringes
1001030V0BBABAB
|
Orencia | Abatacept | Musculoskeletal and Joint Diseases | No data available |
|
Orencia 250mg pdr for concentrate for inf vials
1001030V0BBAAAA
|
Orencia | Abatacept | Musculoskeletal and Joint Diseases | No data available |
|
Orencia 50mg/0.4ml inj pre-filled syringes
1001030V0BBAEAE
|
Orencia | Abatacept | Musculoskeletal and Joint Diseases | No data available |
|
Orencia 87.5mg/0.7ml inj pre-filled syringes
1001030V0BBADAD
|
Orencia | Abatacept | Musculoskeletal and Joint Diseases | No data available |
|
Orencia ClickJect 125mg/1ml inj pre-filled pens
1001030V0BBACAC
|
Orencia | Abatacept | Musculoskeletal and Joint Diseases | No data available |
|
Orudis 100mg capsules
1001010L0BCABAB
|
Orudis | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Orudis 100mg suppositories
1001010L0BCACAP
|
Orudis | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Orudis 50mg capsules
1001010L0BCAAAA
|
Orudis | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Oruvail 150 modified-release capsules
1001010L0BDADAL
|
Oruvail (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Oruvail IM 100mg/2ml solution for injection ampoules
1001010L0BDACAG
|
Oruvail (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Pacifene 200mg tablets
1001010J0BUAAAD
|
Pacifene | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Paramed Ibuprofen 200mg liquid capsules
1001010J0DFAEAA
|
Galpharm (Ibuprofen) | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Pardelprin MR 75mg capsules
1001010K0BVAAAD
|
Pardelprin | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Penicillamine 125mg/5ml oral solution
1001030F0AAAJAJ
|
Penicillamine | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Penicillamine 250mg/5ml oral solution
1001030F0AAAIAI
|
Penicillamine | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Penicillamine 250mg/5ml oral suspension
1001030F0AAALAL
|
Penicillamine | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
|
Penicillamine 50mg/5ml oral solution
1001030F0AAAKAK
|
Penicillamine | Penicillamine | Musculoskeletal and Joint Diseases | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.